Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions

Inclusion Criteria: * Patients of any sex, \>18 years old, diagnosed with sessile or flat polyps, with a diameter greater than or equal to 2 cm, in the intestinal submucosa by the Endoscopy Unit. * The subject has understood and signed an informed consent form (ICF) approved by a Research Ethics Committee (REC) before any study evaluation and commits to completing the study as defined in the protocol. * Not undergoing active treatment with antiplatelet or anticoagulant drugs. * After signing the informed consent, patients are scheduled for lesion resection within \<3 months from their diagnosis. Exclusion Criteria: * Patients with documented allergy to any of the components of the mucosectomy solution or drugs used in sedation. * Pregnant women. * Patients on contraceptive treatment or post-menopausal. * Hematological disorders with uncorrected coagulation abnormalities, with an INR \>= 1.5, or patients undergoing active treatment with antiplatelet or anticoagulant drugs. * Patients with intestinal perforation or obstruction, toxic megacolon, diverticulitis, or inflammatory bowel disease. * Patients with previous partial resection or pending resection. * Patients with lesions classified as Paris type III and/or invasive intestinal carcinoma and/or metastases. Patients with previous treatment of the lesion (radiotherapy, endoscopic, surgical, chemotherapy). * Patients included in another study during the previous month. * Conditions that, in the medical judgment, contraindicate polyp removal. * Absence of a signed informed consent, non-acceptance, or contraindication of surgical or anesthetic techniques (Patients with ASA status: High anesthetic risk (ASA score \> 3)) and difficulty in the patient's understanding of the conditions of the endoscopic procedure. * Endoscopic appearance of invasive malignancy.